Literature DB >> 1818210

In vitro and in vivo investigations of human microsporidia.

E U Canning1, W S Hollister.   

Abstract

The numerous infections of microsporidia which have been diagnosed in patients with AIDS have revealed the potential of these organisms for establishing themselves when the immune status of the host is compromised. Two species of Encephalitozoon, E. cuniculi and E. hellem, have been diagnosed in man, the former infecting a variety of tissues, the latter restricted to the corneal and conjunctival epithelia. These species are morphologically indistinguishable even at the ultrastructural level but can be separated biochemically. Two human sera were found to react with equal intensity in the ELISA on spores of E. cuniculi and E. hellem purified from in vitro cultures, and gave similar binding patterns in Western blots on SDS-PAGE protein profiles of the two species. This has raised questions about the identity of Encephalitozoon infections diagnosed previously in man. The diagnosis of Enterocytozoon bieneusi, which infects the intestinal enterocytes of AIDS patients and is associated with chronic diarrhoea, requires observation of smears or sections of biopsies or specialist observation of stool preparations. In vitro cultures, which would facilitate the raising of specific antisera, have proved difficult to establish. In vitro and in vivo systems for assaying drugs for microsporidia have revealed that albendazole has a marked effect on parasite numbers and morphology but does not eliminate infection, which resurges when drug pressure is removed.

Entities:  

Mesh:

Year:  1991        PMID: 1818210

Source DB:  PubMed          Journal:  J Protozool        ISSN: 0022-3921


  11 in total

1.  A spore counting method and cell culture model for chlorine disinfection studies of Encephalitozoon syn. Septata intestinalis.

Authors:  D M Wolk; C H Johnson; E W Rice; M M Marshall; K F Grahn; C B Plummer; C R Sterling
Journal:  Appl Environ Microbiol       Date:  2000-04       Impact factor: 4.792

Review 2.  Molecular techniques for detection, species differentiation, and phylogenetic analysis of microsporidia.

Authors:  C Franzen; A Müller
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

3.  In vitro efficacy of nikkomycin Z against the human isolate of the microsporidian species Encephalitozoon hellem.

Authors:  E Bigliardi; A M Bernuzzi; S Corona; S Gatti; M Scaglia; L Sacchi
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

4.  Detection of microsporidia by indirect immunofluorescence antibody test using polyclonal and monoclonal antibodies.

Authors:  A M Aldras; J M Orenstein; D P Kotler; J A Shadduck; E S Didier
Journal:  J Clin Microbiol       Date:  1994-03       Impact factor: 5.948

5.  Flow cytometric analysis of microsporidia belonging to the genus Encephalitozoon.

Authors:  D M Moss; G P Croppo; S Wallace; G S Visvesvara
Journal:  J Clin Microbiol       Date:  1999-02       Impact factor: 5.948

6.  Susceptibility of Encephalitozoon cuniculi to several drugs in vitro.

Authors:  F F Franssen; J T Lumeij; F van Knapen
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

7.  In vitro model to assess effect of antimicrobial agents on Encephalitozoon cuniculi.

Authors:  B Beauvais; C Sarfati; S Challier; F Derouin
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

Review 8.  Human microsporidial infections.

Authors:  R Weber; R T Bryan; D A Schwartz; R L Owen
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

9.  Ultrastructure of the development of a species of Encephalitozoon cultured from the eye of an AIDS patient.

Authors:  S S Desser; H Hong; Y J Yang
Journal:  Parasitol Res       Date:  1992       Impact factor: 2.289

10.  Latent microsporidiosis caused by Encephalitozoon cuniculi in immunocompetent hosts: a murine model demonstrating the ineffectiveness of the immune system and treatment with albendazole.

Authors:  Michaela Kotkova; Bohumil Sak; Dana Kvetonova; Martin Kvac
Journal:  PLoS One       Date:  2013-04-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.